Search website

If you cannot find, what you are looking for, try searching for it below or visit our FAQ-page.

Close

2015.05.01

Tillotts Pharma supports the World IBD Day

Press Release

RHEINFELDEN, Switzerland, May 1, 2015 – The World IBD Day takes place annually on May 19th. On this day, patient associations organize a number of events and activities worldwide to raise awareness of IBD and its impact on the quality of life of many people in Europe and worldwide. At Tillotts Pharma, we are committed to providing support beyond medication and are supporting initiatives organized by patient associations in the UK, Sweden, Czech Republic, Ireland and by the EFCCA (European Federation of Crohn’s and ulcerative Colitis Associations).

Inflammatory bowel diseases (IBDs), such as ulcerative colitis (UC) and Crohn’s disease, affect up to three million people in Europe with the majority of patients reporting that their condition has negatively affected their social and personal life, as revealed by the UCandMETM survey.

Please download here the flyer to the World IBD Day.
For more information on the IBD Day please visitwww.worldibdday.org

For more information, please contact:

Tillotts Pharma AG
Federica Ricatto, Senior Communications Manager
Phone:  +41 61 935 2749
Email

 

About Tillotts
Tillotts Pharma AG, part of the Zeria Group, is a fast-growing specialty pharma company with 200 employees in Switzerland and abroad. Tillotts is dedicated to the development, in/out-licensing and commercialization of innovative pharmaceutical products, medical devices and diagnostics, all in the field of gastroenterology. Please visit our website www.tillotts.com.

Tillotts successfully markets its own products Asacol® and Colpermin® as well as in-licensed products, such as Simtomax®, in over 55 countries through its own affiliates within Europe and a carefully chosen network of gastroenterology-focused marketing partners throughout the world.

About Zeria
Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries. For more information about Zeria please visit www.zeria.co.jp.

 

All trademarks used or mentioned in this release are protected by law. Tillotts’ trademarks include Asacol®, Octasa®, Fivasa®, Lixacol®, Asacolon®, Colpermin®, and are either registered or applied for in up to 70 countries. Asacol® is a registered trademark by Actavis in the United States of America, Canada, and the United Kingdom. Asacol® is a registered trademark in Italy by Giuliani and in Switzerland by Sanofi. Colpermin® is a registered trademark by Johnson & Johnson for the United Kingdom and Ireland.